New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs Epithalon

Orforglipron vs Epithalon

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Anti-Aging & Longevity
Epithalon
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
Half-Life
~12 hours (once-daily oral dosing)
2–4 hours
Admin Route
Oral
SubQ, Sublingual
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
5–10 mg total per cycle
Frequency
Once daily
0.5–1 mg daily
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Activates telomerase enzyme, extending telomere length
  • May slow cellular and biological aging
  • Regulates melatonin production and circadian rhythms
  • Improves sleep quality
  • Powerful antioxidant properties
  • May reduce incidence of age-related diseases
  • Supports immune system function
  • Studied for cancer prevention properties in animal models
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Injection site irritation (mild)
  • Temporary sleep changes during cycle (usually improves)
  • Rare: fatigue
Stacks With